A 12 weeks, randomized, double-blind, placebo-controlled human trial of unripe Bokbunja Extract on decrease of body fat

A 12 weeks, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of unripe Bokbunja Extract on decrease of body fat

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0006298

Enrollment

140

Registered

2021-06-29

Start date

2020-03-17

Completion date

Unknown

Last updated

2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : • unripe Bokbunja Extract group: 1 times a day, 1 tablet once, before meal, for 12 weeks(800 mg/day, 600 mg/day for unripe Bokbunja Extract) • Placebo group: 1 times a day, 1 tab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) 25 = BMI = 34.9 kg/m2 or 25%(male), 30%(female) =body fat percentage 2) Participants who have fully understood information provided about the study, voluntarily decided to participate, and agreed to comply with precautions

Exclusion criteria

Exclusion criteria: 1) Participants who have had a weight change of 10% of more within the 3 months prior to the screening examination. 2) Participants with a clinically significant disease requiring treatment (i.e., acute or chronic cardiovascular system, endocrine system, immune system, respiratory system, kidney and urinary system, neuropsychiatric system, musculoskeletal inflammation, inflammatory disease, blood and tumor disease, gastrointestinal disease, etc.) 3) Fasteners 4) Participants with a history of antipsychotic medication use within 3 months prior to the screening examination. 5) Participants who have participated in other interventional clinical trials within 3 months prior to the screening examination, or plan to participate in other interventional clinical trials. 6) Participants who are judged ineligible to participate in the trial by the principal investigator for other reasons, including laboratory test outcomes.

Design outcomes

Primary

Measure	Time frame
Fat mass by DEXA(Dual-energy X-ray absorptiometry);Percent Body Fat by DEXA(Dual-energy X-ray absorptiometry)	—

Secondary

Measure	Time frame
weight;Body Mass Index(BMI)	—

Countries

Korea, Republic of

Contacts

Public ContactJeonghan Lee

Wonkwang University. Iksan Korean Medicine Hospital

milpaso@wku.ac.kr+82-63-859-2807

Outcome results